- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Regen BioPharma, Inc. Provides Shareholder Update on Company's Activities and Direction | 1 | GlobeNewswire (USA) | ||
| 02.11. | Regen BioPharma vereinbart Schuldschein über 125.000 $ und 10-Millionen-$-Equity-Line mit Coventry | 2 | Investing.com Deutsch | ||
| 02.11. | Regen BioPharma Inc - 8-K, Current Report | - | SEC Filings | ||
| 17.08. | Regen BioPharma Inc - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.08. | Regen BioPharma Inc - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 3 | SEC Filings | ||
| REGEN BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 15.07. | Regen BioPharma Inc - 8-K, Current Report | 1 | SEC Filings |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GENMAB | 469,30 | -2,72 % | Genmab Profit Drops In Q3, Maintains FY26 Revenue Outlook | BRUSSELS (dpa-AFX) - Thursday, Genmab A/S (GMAB) announced its financial results for the third quarter, reporting a net profit of $342 million, or $5.581 a share, compared with $401 million... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 92,22 | -0,04 % | Halozyme Therapeutics, Inc.: U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE Technology for the Treatment of Advanced Head and Neck Cancer | Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced... ► Artikel lesen | |
| BASILEA | 77,50 | -0,13 % | Basilea Pharmaceutica International Ltd, Allschwil: Starke Verkaufszahlen für Cresemba (Isavuconazol) in Europa lösen USD 37.5 Mio. Meilensteinzahlung an Basilea aus | Ad hoc-Mitteilung gemäss Art. 53 KR
Allschwil, 03. November 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,370 | -1,75 % | Arbutus Biopharma GAAP EPS of $0.30 beats by $0.32, revenue of $0.3M misses by $0.7M | ||
| INNOVIVA | 17,100 | 0,00 % | Innoviva GAAP EPS of -$1.03 misses by $1.37, revenue of $106.12M misses by $9.19M | ||
| BIOARCTIC | 28,680 | +1,49 % | Novartis kappt BioArctic-Pakt: Was der Stillstand verdeckt | ||
| ANAPTYSBIO | 42,970 | 0,00 % | AnaptysBio, Inc.: Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update | Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growthPositive interim results from the pivotal AZUR-1 trial of Jemperli... ► Artikel lesen | |
| XENCOR | 35,200 | -0,56 % | Xencor GAAP EPS of $0.50 beats by $0.83, revenue of $116.52M beats by $53.53M | ||
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen |
Das Unternehmen REGEN BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REGEN BIOPHARMA INC finden Sie auf Wallstreet Online.